10.6084/m9.figshare.9794933.v1 Susan J. Keam Susan J. Keam Pretomanid: First Approval Adis Journals 2019 Pretomanid TB XDR TB MDR TB Review Adis Insight Report 2019-10-04 00:23:17 Online resource https://adisjournals.figshare.com/articles/online_resource/Pretomanid_First_Approval/9794933 <div><b>Compliance with Ethical Standards</b></div><div><br></div><div><i>Funding</i>: The preparation of this review was not supported by any external funding.</div><div><br></div><div><i>Conflicts of interest:</i>  During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan Keam is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest</div><div><br></div><div>Additional information about this Adis Drug Review can be found <b><a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a></b><br></div><div><br></div><div>Abstract</div><div><br></div><div><p>Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimens, has been developed by the Global Alliance for TB Drug Development (TB Alliance) under license from Novartis, for the treatment for tuberculosis (TB). TB Alliance has licensed Mylan to manufacture and commercialize pretomanid for use as part of the BPaMZ and BPaL regimens. The license is non-exclusive in low- and middle-income countries and exclusive in high-income markets. Pretomanid, as part of the BPaL regimen, was recently approved in the USA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway for the treatment of extensively drug-resistant (XDR) TB and treatment-intolerant or non-responsive multidrug-resistant (MDR) TB. Pretomanid is also under regulatory review in the EU. This article summarizes the milestones in the development of pretomanid leading to this first regulatory approval.</p></div><div><br></div><div>© Springer Nature Switzerland AG 2019<br></div><div><br></div>